Primary Versus Metastatic Cancer: Gene Expression Profiling

  • Jaishree Jagirdar
  • Philip T. Cagle
Part of the Molecular Pathology Library book series (MPLB, volume 1)


Accurate identification of the primary site of a cancer is important to predict prognosis and select appropriate therapy. Approximately 10%–15% of cancers initially present as metastases to solid organs, body cavities, or lymph nodes. However, the primary site of the metastatic cancer is not always clinically apparent. About 3%–5% of all cancers are carcinomas of unknown primary, making this type of tumor one of the 10 most frequent cancers in the world.1, 2, 3, 4, 5, 6, 7, 8, 9 Even with autopsy, in a series published in 2005 by Al-Brahim et al., a primary site was identified in only 51% of 53 cases of metastatic cancer of unknown origin.9


Renal Cell Carcinoma Reverse Transcription Polymerase Chain Reaction Primary Lung Cancer Pseudomyxoma Peritonei Prostate Stem Cell Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nystrom JS, Weiner JM, Heffelfinger-Juttner J, et al. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53–58.PubMedGoogle Scholar
  2. 2.
    Burton EC, Troxclair DA, Newman WP 3rd. Autopsy diagnoses of malignant neoplasms: how often are clinical diagnoses incorrect? JAMA 1998;280:1245–1248.CrossRefPubMedGoogle Scholar
  3. 3.
    Hillen HFP. Unknown primary tumours. Postgrad Med J 2000;76:690–693.CrossRefPubMedGoogle Scholar
  4. 4.
    Levi F, Te VC, Erler G, et al. Epidemiology of unknown primary tumours. Eur J Cancer 2002;38:1810–1812.CrossRefPubMedGoogle Scholar
  5. 5.
    van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur J Cancer 2002;38:409–413.CrossRefPubMedGoogle Scholar
  6. 6.
    Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003;39:1990–2005.CrossRefPubMedGoogle Scholar
  7. 7.
    Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776–1785.CrossRefPubMedGoogle Scholar
  8. 8.
    Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 2005;54:243–250.CrossRefPubMedGoogle Scholar
  9. 9.
    Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol 2005;9:77–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma: A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12–19.PubMedGoogle Scholar
  11. 11.
    Cagle PT. Differential diagnosis between primary and metastatic carcinomas. In Brambilla C, Brambilla E, eds. Lung Tumors: Fundamental Biology and Clinical Management. New York: Marcel Dekker; 1999:127–137.Google Scholar
  12. 12.
    Dail D, Cagle P, Marchevsky A, et al. Tumours of the lung: metastases to the lung. In Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK, eds. World Health Organization Classification of Tumours, Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC; 2004.Google Scholar
  13. 13.
    Cagle PT. Carcinoma of the lung. In Churg AM, Myers JL, Tazelaar HD, Wright JL, eds. Pathology of the Lung, 3rd ed. New York: Thieme; 2005:413–479.Google Scholar
  14. 14.
    Laga AC, Allen T, Bedrossian C, et al. Metastatic carcinoma. In Cagle PT, ed. The Color Atlas and Text of Pulmonary Pathology. New York: Lippincott Williams & Wilkins; 2005:77–79.Google Scholar
  15. 15.
    Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766–3772.CrossRefPubMedGoogle Scholar
  16. 16.
    McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody “renal cell carcinoma marker.” Am J Surg Pathol 2001;25(12):1485–1492.CrossRefPubMedGoogle Scholar
  17. 17.
    Butnor KJ, Nicholson AG, Allred DC, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006;130(6):823–827.PubMedGoogle Scholar
  18. 18.
    Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388–7393.PubMedGoogle Scholar
  19. 19.
    Dennis JL, Vass JK, Wit EC, et al. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res 2002;62:5999–6005.PubMedGoogle Scholar
  20. 20.
    Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003;54:73–87.CrossRefPubMedGoogle Scholar
  21. 21.
    Sorensen PH, Triche TJ. Gene fusions encoding chimeric transcription factors in solid tumors. Semin Cancer Biol 1996;7:3–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Hill DA, O’Sulivan MJ, Zhu X, et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol 2002;26:965–977.CrossRefPubMedGoogle Scholar
  23. 23.
    Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286;531–537.CrossRefPubMedGoogle Scholar
  24. 24.
    Khan J, Wei JS, Ringner M, Saal LH, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673–679.CrossRefPubMedGoogle Scholar
  25. 25.
    Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 2001;98:15149–15154.CrossRefPubMedGoogle Scholar
  26. 26.
    Giordano TJ, Shedden KA, Schwartz DR, et al. Organspecific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001;159:1231–1238.PubMedGoogle Scholar
  27. 27.
    Bloom G, Yang IV, Boulware D, et al. Multi-platform, multisite, microarray-based human tumor classification. Am J Pathol 2004;164:9–16.PubMedGoogle Scholar
  28. 28.
    Shedden KA, Taylor JM, Giordano TJ, et al. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 2003;163:1985–1995.PubMedGoogle Scholar
  29. 29.
    Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005;65:4031–4040.CrossRefPubMedGoogle Scholar
  30. 30.
    Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006;130:465–473.PubMedGoogle Scholar
  31. 31.
    Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006;24(11):1679–1688.CrossRefPubMedGoogle Scholar
  32. 32.
    Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120–129.CrossRefPubMedGoogle Scholar
  33. 33.
    Pairolero PC, Williams DE, Bergstrahl EL, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984;38:331–338.PubMedGoogle Scholar
  34. 34.
    Rosengart TK, Martini N, Ghosn P, et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg 1991;52:773–778.PubMedCrossRefGoogle Scholar
  35. 35.
    Carey FA, Donnelly SC, Walker WS, et al. Synchronous primary lung cancers: prevalence in surgical material and clinical implications. Thorax 1993;48:344–346.CrossRefPubMedGoogle Scholar
  36. 36.
    Rohwedder JJ, Weatherbee L. Multiple primary bronchogenic carcinoma with a review of the literature. Am Rev Respir Dis 1974;109:435–445.PubMedGoogle Scholar
  37. 37.
    Hida T, Ariyoshi Y, Sugiora T, et al. Synchronous lung cancer presenting with small cell carcinoma and adenocarcinoma. Chest 1993;104:1602–1604.CrossRefPubMedGoogle Scholar
  38. 38.
    Martini N, Melamed MR. Multiple primary lung cancers. Thorac Cardiovasc Surg 1975;70:606–612.Google Scholar
  39. 39.
    Neugut AI, Sherr D, Robinson E, et al. Differences in histology between first and second primary lung cancer. Cancer Epidemiol Biomarkers Prev 1992;1:109–112.PubMedGoogle Scholar
  40. 40.
    Antakli T, Schefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg 1995;59:863–867.CrossRefPubMedGoogle Scholar
  41. 41.
    Deschamps C, Pairolero PC, Trastek VF, et al. Multiple primary lung cancers. Results of surgical treatment. J Thorac Cardiovasc Surg 1990;99:769–777.PubMedGoogle Scholar
  42. 42.
    Wu SC, Lin ZQ, Xu CW, et al. Multiple primary lung cancers. Chest 1987;92:892–896.CrossRefPubMedGoogle Scholar
  43. 43.
    Cunha JD, Herndon JE II, Herzan DL, et al. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer 2005;48:241–246.CrossRefPubMedGoogle Scholar
  44. 44.
    Yang HK, Linnoila RI, Conrad NK, et al. TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. Int J Cancer 1995;64:229–233.CrossRefPubMedGoogle Scholar
  45. 45.
    Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 1999;154:1849–1855.PubMedGoogle Scholar
  46. 46.
    Fujita M, Enomoto T, Wada H, et al. Application of clonal analysis. Differential diagnosis for synchronous primary ovarian and endometrial cancers and metastatic cancer. Am J Clin Pathol 1996;105:350–359.PubMedGoogle Scholar
  47. 47.
    Cuatrecasas M, Matias-Guiu X, Prat J, et al. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol 1996;20:739–746.CrossRefPubMedGoogle Scholar
  48. 48.
    Koness RJ, King TC, Schechter S, et al. Synchronous colon carcinomas: molecular-genetic evidence for multicentricity. Ann Surg Oncol 1996;3:136–143.CrossRefPubMedGoogle Scholar
  49. 49.
    Lau DH, Yang B, Hu R, et al. Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis. Diagn Mol Pathol 1997;6:179–184.CrossRefPubMedGoogle Scholar
  50. 50.
    Yamamoto S, Tada M, Lee CC, et al. p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry. Jpn J Cancer Res 2000;91:181–189.PubMedGoogle Scholar
  51. 51.
    Goto K, Konomoto T, Hayashi K, et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod Pathol 1997;10:428–437.PubMedGoogle Scholar
  52. 52.
    Werness BA, DiCioccio RA, Piver MS. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. Hum Pathol 1997;28:626–630.CrossRefPubMedGoogle Scholar
  53. 53.
    Lyda MH, Noffsinger A, Belli J, et al. Multifocal neoplasia involving the colon and appendix in ulcerative colitis: pathological and molecular features. Gastroenterology 1998;115:1566–1573.CrossRefPubMedGoogle Scholar
  54. 54.
    Eguchi K, Yao T, Konomoto T, et al. Discordance of p53 mutations of synchronous colorectal carcinomas. Mod Pathol 2000;13:131–139.CrossRefPubMedGoogle Scholar
  55. 55.
    Ribeiro U, Safatle-Ribeiro AV, Posner MC, et al. Comparative p53 mutational analysis of multiple primary cancers of the upper aerodigestive tract. Surgery 1996;120:45–53.CrossRefPubMedGoogle Scholar
  56. 56.
    Takahashi T, Habuchi T, Kakehi Y, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58:5835–5841.PubMedGoogle Scholar
  57. 57.
    Emmert-Buck MR, Chuaqui R, Zhuang Z, et al. Molecular analysis of synchronous uterine and ovarian endometrioid tumors. Int J Gynecol Pathol 1997;16:143–148.CrossRefPubMedGoogle Scholar
  58. 58.
    Krebs PA, Albuquerque A, Quezado M. The use of micro-satellite instability in the distinction between synchronous endometrial and colonic adenocarcinomas. Int J Gynecol Pathol 1999;18:320–324.CrossRefPubMedGoogle Scholar
  59. 59.
    Lin WM, Forgacs E, Warshal DP, et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 1998;4:2577–2583.PubMedGoogle Scholar
  60. 60.
    Scholes AG, Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res 1998;58:2003–2006.PubMedGoogle Scholar
  61. 61.
    Shimizu S, Yatabe Y, Koshikawa T. High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res 2000;6:3994–3999.PubMedGoogle Scholar
  62. 62.
    Hiroshima K, Toyozaki T, Kohno H. Synchronous and metachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int 1998;48:869–876.CrossRefPubMedGoogle Scholar
  63. 63.
    Huang J, Behrens C, Dimopulo O, et al. Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. Ann Diagn Pathol 2001;5(6):321–329.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Jaishree Jagirdar
    • 1
  • Philip T. Cagle
    • 2
    • 3
  1. 1.University of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Pathology and Laboratory MedicineWeill Medical College of Cornell UniversityNew York
  3. 3.The Methodist HospitalHoustonUSA

Personalised recommendations